Category: Company News
-

American Fusion Highlights Texatron Testing as It Targets AI and Data Center Power Market
American Fusion says its Texatron program is targeting unity or beyond-unity testing by the end of 2026, while prospective commercial opportunities remain dependent on successful validation. Key Investor Takeaways Why AMFN Stock Is in Focus American Fusion provided additional details about its Texatron testing and commercialization strategy through an interview with Executive Chairman Brent Nelson.…
-

Black Dragon Resource Announces Funding Commitment for Share Retirement and Sand Plant Acquisition
Black Dragon Resource says its chairman and CEO is committing funds without convertible notes or toxic investments as the company targets share retirement, an acquisition and an upgrade to a higher trading tier. Key Investor Takeaways Why BDGR Stock Is in Focus Black Dragon Resource announced a financial commitment from its chairman and CEO aimed…
-

AeroVironment Secures First International LOCUST Counter-Drone System Order Worth More Than $50 Million
The first overseas purchase of AeroVironment’s LOCUST laser weapon system expands the directed energy platform beyond its U.S. deployments and follows a $464.8 million U.S. Army contract. Key Investor Takeaways Why AVAV Stock Is in Focus AeroVironment has secured its first international LOCUST counter-drone system order, moving the high-energy laser platform into an overseas commercial…
-

Medicus Pharma Identifies 200 µg SkinJect Patch as Lead Development Dose After Phase 2 Study
The completed SKNJCT-003 study is shaping Medicus Pharma’s next clinical strategy, with the 200 µg dose moving into an FDA-authorized Gorlin syndrome program while the company considers partnerships for nodular basal cell carcinoma. Key Investor Takeaways Why MDCX Stock Is in Focus Medicus Pharma has published an abridged final Clinical Study Report for its Phase…
-

1-800-FLOWERS.COM Reports Revenue Decline as Company Evaluates Capital Raising Options
Fiscal 2026 revenue fell 10.8% to $1.50 billion and adjusted EBITDA declined to $2.9 million, while the company amended its credit agreement and began reviewing financing and asset-sale alternatives. Key Investor Takeaways Why FLWS Stock Is in Focus 1-800-FLOWERS.COM reported lower fiscal 2026 revenue and adjusted profitability while outlining measures intended to provide additional financial…
-

Roche’s Genentech Gets FDA Priority Review for Enspryng in MOGAD
The FDA is expected to decide by January 10, 2027, after a Phase III study showed Enspryng reduced the risk of MOGAD relapse by 68% versus placebo. Key Investor Takeaways Why RHHBY Stock Is in Focus The FDA granted Priority Review to Genentech’s application seeking to expand Enspryng into myelin oligodendrocyte glycoprotein antibody-associated disease, or…
-

Medical Care Technologies Configures StrainScan Pro AI Vision Modules for High-Value Produce
StrainScan Pro is being tailored for leafy greens, berries, tomatoes and tree fruit as Medical Care Technologies targets crop-specific visual quality inspection applications. Key Investor Takeaways Why MDCE Stock Is in Focus Medical Care Technologies is configuring StrainScan Pro AI vision modules around leafy greens, berries, tomatoes and tree fruit rather than relying on a…
-

American Gold & Copper Signs $10 Million Rimrock Copper-Gold Project Acquisition in Nevada
American Gold & Copper Inc. (USOTC:AGCI) has signed a definitive $10 million acquisition agreement for the Rimrock Copper-Gold Project in Nevada, adding 77 mining claims covering approximately 1,540 acres and committing about $1.5 million to an initial 18-month exploration programme. Key Investor Takeaways Why AGCI Stock Is in Focus American Gold & Copper has moved…
-

Rezolute FDA Review Continues After Phase 3 sunRIZE Study Missed Primary Endpoint
Rezolute (NASDAQ:RZLT) said the FDA is continuing its review of additional Phase 3 sunRIZE data for ersodetug in congenital hyperinsulinism after the study failed to meet its primary endpoint, leaving the potential regulatory path unresolved and without a specific timeline for agency feedback. Key Investor Takeaways Why RZLT Stock Is in Focus Rezolute’s regulatory discussions…
-

SunHydrogen Commercialization Path Targets Repeatable Full-Size Hydrogen Module Performance
SunHydrogen (USOTC:HYSR) outlined its commercialization path for its renewable hydrogen technology, setting year-end 2026 objectives around repeatable full-size module performance, integrated-system reliability and manufacturing consistency while confirming that it has not yet secured a customer or offtake agreement. Key Investor Takeaways Why HYSR Stock Is in Focus SunHydrogen provided new detail on the engineering and…